NEW YORK--(BUSINESS WIRE)--Enzo Biochem (NYSE:ENZ) announced that it has been included in the broad-market Russell 3000® Index, Russell 2000® Index and Russell Global Index, which reconstituted after the market closed on Friday, June 24th.
The Russell 3000 Index is a capitalization-weighted stock market index, maintained by the Russell Investment Group that seeks to be a benchmark of the entire U.S stock market. It measures the performance of the 3,000 largest publicly held companies incorporated in the U.S. based on market capitalization. It represents approximately 98% of the US public equity market.
Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by objective, market-capitalization rankings and style attributes.
"Our addition to the Russell 3000 is an important milestone that reflects the company’s progress across all of its business units, “said Barry Weiner, President. “Enzo’s inclusion in the Index should increase awareness of the company among the investment community and broaden our institutional shareholder base.”
The FTSE Global Equity Index Series covers around 7,400 securities in 46 different countries - covering every equity and sector relevant to international investors’ needs. Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10 trillion in assets are benchmarked against the Russell US indexes.
About FTSE Russell
FTSE Russell is a global index leader and data provider that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $10 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
For more information, visit www.ftserussell.com.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
